Sep 11 |
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
|
Sep 4 |
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
|
Aug 26 |
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
|
Aug 19 |
LIXTE Biotechnology Provides Update On Recent Activities and Developments
|
Aug 15 |
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
|
Aug 15 |
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
|
Jun 14 |
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
|
Jun 14 |
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
|
Jun 6 |
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
|
Jun 3 |
Lixte Biotechnology appoints Jan Schellens as CMO
|